Publications:
Our Research

Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial

Combination Respiratory Vaccine Containing Recombinant SARS-CoV-2 Spike and Quadrivalent Seasonal Influenza Hemagglutinin Nanoparticles with Matrix-M Adjuvant

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

Current Protocol for Phase 3 Clinical Trial of NVX-CoV2373 in the U.K.

Novavax COVID-19 Program Update for World Vaccine Congress

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines

A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351

Current Protocol for Phase 2b Clinical Trial of NVX-CoV2373 in South Africa

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice